Searched for
GILEAD ACQUISITION
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...- Why US stock market crashes today? Dow, S&P 500 and Nasdaq in deep red – Iran tensions rise and surging oil prices shake Wall StreetWhy US stock market crashes today? Dow Jones, S&P 500 and Nasdaq in deep red today. Wall Street turns sharply lower as US stock market cras...
- Eli Lilly bets on next-generation cell therapy with $2.4 billion deal for OrnaEli Lilly will buy Orna Therapeutics for up to $2.4 billion in cash, gaining access to a technology that allows patients' own cells to gen...
- Zydus aims to launch first new drug in US by early 2026Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition o...
- Gilead nears deal to buy Immunomedics for more than $20 billion: ReportA deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer ca...
- Stocks in the news: RIL, Vodafone Idea, Tata Motors, Dr Reddy's Labs and BHELCSB Bank, JK Tyre, Pfizer, Shalby, Shoppers Stop and Ramky Infra are among companies which will announce Q4 results today.
- AstraZeneca approaches Gilead about potential mergerAstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger.
- Stocks in the news: Cipla, Aurobindo Pharma, GMR Infra, Indiabulls Real Estate and Ashok leylandHere are a few stocks which may create some buzz in Friday’s trade.
- Gilead to buy Kite for $11.9 billion in cancer drug megadealWith Kite, Gilead will gain cancer therapies and experimental drugs in one of the most promising fields in oncology, in addition to its hep...
- Merck wins record $2.5 billion patent verdict against GileadThe judge in the case had already decided that Merck’s patent was infringed by Gilead’s Sovaldi and Harvoni, which account for more than ha...
- Nifty down 10% from record high: Top 10 stocks to bet onIf expert commentaries are anything to go by, then technically, Nifty50 looks weak and it may test 7,900-7,980 in the near term.
- Can co-invest with government in health: Cipla's Subhanu SaxenaOver the 2-year period with Subhanu Saxena at the helm, Cipla's revenues have grown by over 30% to nearly Rs 11,500 crore.
- Midcap stocks catching analysts' frenzy; top 10 stocks to bet onThe sharp correction in the Indian markets provides a good opportunity for investors to add midcap stocks to their portfolio, say experts.
- Sharekhan’s top 12 stocks which can deliver up to 50% return in next 6-12 monthsThe S&P BSE Sensex lost 4.8% in March, the most since February 2013. Brokerage Sharekhan though believes that most of the issues are tempor...
- Pharma in 2014: Deals worth billions and fines worth millionsRanbaxy, founded by the family of Malvinder and Shivinder Mohan Singh, was at the centre of most of the developments for major part of the ...
- Cipla chief Yusuf K Hamied grooms niece & nephew Samina Vaziralli & Kamil Hamied as genext leadersEven as Hamied prepares genext leaders for Cipla, it’s humanitarian face is out to shake up industry by delivering affordable biosimilar dr...
- We will deliver biotech at a Dollar a day. Wait and see: Yusuf Khwaja Hamied, Chairman of CiplaEvery country’s patent laws are need-based to that country. That’s what I am trying to fight, and nobody is listening, Hamied said.
- 5 Pharma stocks that propelled BSE Healthcare to lifetime highDespite the concerns on import alerts from the USFDA and recent drug recalls, the pharma sector was one of the top performers in the last q...
- Cipla teams up with Gilead Lifesciences to make Hepatitis C drug under voluntary licenceOn the face of it, there is nothing wrong with this kind of a deal. Pharma companies ink many such pacts on a regular basis.
- Pfizer’s Wyeth bid may trigger rush for M&AsPfizer’s potential purchase of Wyeth for more than $60 billion may set off a rush to consolidate in an industry buffeted by a thinner pipel...
Load More
